Indian Journal of Medical and Paediatric Oncology

metrics 2024

Fostering knowledge for a brighter future in oncology.

Introduction

Indian Journal of Medical and Paediatric Oncology, published by THIEME MEDICAL PUBL INC, serves as a crucial platform for disseminating research and clinical studies in the realms of oncology and paediatrics. With an ISSN of 0971-5851 and an E-ISSN of 0975-2129, this journal plays a pivotal role in addressing the challenges and advancements in important areas of child health and cancer treatment. Although the journal is currently ranked in the Q4 category for both Oncology and Pediatrics, Perinatology and Child Health, its ongoing commitment to publishing quality research from 2009 to 2024 signifies its relevance in the academic community. Positioned in India and accessible to a global audience, this journal aims to foster a comprehensive understanding of medical and paediatric oncology, thereby influencing clinical practices and enhancing patient care. Researchers, practitioners, and students alike can benefit from its diverse range of articles, offering insights into the latest scientific discoveries and therapeutic approaches in these critical fields.

Metrics 2024

SCIMAGO Journal Rank0.12
Journal Impact Factor0.30
Journal Impact Factor (5 years)0.30
H-Index30
Journal IF Without Self0.30
Eigen Factor0.00
Normal Eigen Factor0.08
Influence0.07
Immediacy Index0.10
Cited Half Life7.70
Citing Half Life8.20
JCI0.04
Total Documents1466
WOS Total Citations779
SCIMAGO Total Citations1747
SCIMAGO SELF Citations64
Scopus Journal Rank0.12
Cites / Document (2 Years)0.20
Cites / Document (3 Years)0.15
Cites / Document (4 Years)0.21

Metrics History

Rank 2024

Scopus

Pediatrics, Perinatology and Child Health in Medicine
Rank #276/330
Percentile 16.36
Quartile Q4
Oncology in Medicine
Rank #351/404
Percentile 13.12
Quartile Q4

IF (Web Of Science)

ONCOLOGY
Rank 309/322
Percentile 4.20
Quartile Q4

JCI (Web Of Science)

ONCOLOGY
Rank 315/322
Percentile 2.17
Quartile Q4

Quartile History

Similar Journals

BRITISH JOURNAL OF CANCER

Pioneering Insights in Oncology Since 1947.
Publisher: SPRINGERNATUREISSN: 0007-0920Frequency: 24 issues/year

The British Journal of Cancer, published by SpringerNature, stands as a preeminent resource in the fields of Cancer Research and Oncology, with a distinguished history of publication dating back to 1947. With its Q1 rank in both categories for 2023, this journal is among the top-tier publications, offering cutting-edge research and insights into the biology, etiology, and treatment of cancer. The journal’s rigorous peer-review process ensures that readers are presented with high-quality studies that contribute to the advancement of cancer knowledge and clinical practice. Operating from the United Kingdom, it has garnered a notable impact factor and ranks impressively within Scopus, making it an essential publication for researchers, healthcare professionals, and students who are dedicated to understanding cancer's complexities. Access to the journal's articles is available in traditional formats, providing a versatile platform for disseminating pivotal research. As we move towards a future where cancer treatment and prevention remain crucial, the British Journal of Cancer continues to play a vital role in shaping the dialogue and discoveries within the oncology community.

BULLETIN DU CANCER

Innovative insights shaping the future of oncology.
Publisher: ELSEVIER MASSON, CORP OFFISSN: 0007-4551Frequency: 12 issues/year

BULLETIN DU CANCER is a pivotal academic journal dedicated to the field of oncology, providing a platform for innovative research and insights into cancer treatment and diagnostics. Published by Elsevier Masson, Corp Off in France, this journal has been a part of the scientific community since 1966, and is committed to sharing critical findings that influence clinical practices and improve patient outcomes. Despite its recent rankings placing it in the Q4 category for Cancer Research and Q3 for Hematology and other related fields, BULLETIN DU CANCER remains essential for those interested in the latest developments in cancer biology and treatment methodologies. With an emphasis on both basic and clinical research, it serves as a valuable resource for researchers, healthcare professionals, and students seeking to deepen their understanding in various dimensions of oncology. This journal is particularly relevant as it continues to spotlight emerging research trends and supports the global imperative to combat cancer more effectively.

eCancerMedicalScience

Connecting minds to conquer cancer.
Publisher: eCancer Global FoundationISSN: 1754-6605Frequency:

eCancerMedicalScience, a leading open-access journal published by the eCancer Global Foundation, is dedicated to advancing the field of cancer research and oncology. With its inception in 2007, this esteemed journal has emerged as a pivotal platform for disseminating groundbreaking research, innovative treatments, and comprehensive reviews in the cancer domain. Based in the United Kingdom, eCancerMedicalScience has continuously contributed to the academic community with its rigorous peer-review process and broad-ranging scope, now encompassing topics from clinical oncology to molecular biology. Currently ranked in the Q3 quartile for both Cancer Research and Oncology in 2023, the journal provides a significant opportunity for researchers, professionals, and students to access valuable insights and share their findings within a global network. The commitment to open access ensures that knowledge is readily available, fostering collaborative efforts to combat cancer and improve patient outcomes.

Onkologija

Empowering the fight against cancer through open access.
Publisher: INST ONCOLOGY LJUBLJANAISSN: 1408-1741Frequency: 2 issues/year

Onkologija is a distinguished open-access journal dedicated to the field of oncology, published by the Institute of Oncology Ljubljana. With its ISSN 1408-1741 and E-ISSN 1581-3215, this journal has become a crucial platform for researchers and healthcare professionals since its transition to open-access in 2008, allowing widespread dissemination of critical findings and innovations in cancer research and treatment. Located in Ljubljana, Slovenia, the journal aims to bridge the gap between clinical practice and research by publishing high-quality original articles, reviews, and case studies that address pivotal issues in oncology. Although specific metrics such as HIndex and Scopus ranks are currently unavailable, Onkologija’s commitment to advancing oncology knowledge is evident in its engaging publications that attract a diverse readership, making it an essential resource for anyone invested in the battle against cancer.

Tumori Journal

Elevating Oncology Knowledge for a Healthier Tomorrow.
Publisher: SAGE PUBLICATIONS LTDISSN: 0300-8916Frequency: 6 issues/year

Tumori Journal is a distinguished publication in the field of oncology, dedicated to advancing the understanding and treatment of cancer since its inception in 1946. Published by SAGE Publications Ltd, this Italian journal serves as a pivotal platform for researchers, clinicians, and academicians to disseminate cutting-edge findings in cancer research and related areas of medicine. With an impressive record of contributions spanning multiple decades, Tumori Journal aims to foster collaboration and dialogue among professionals in the oncology community. Although classified in the Q4 category for Cancer Research and the Q3 category for both Medicine (miscellaneous) and Oncology as of 2023, the journal continues to draw interest with its rigorous peer-review process and commitment to quality. Researchers are encouraged to explore innovative methodologies and share impactful clinical insights through the journal, which also ranks within the top tiers of Scopus metrics for oncology and cancer research domains. With a growing emphasis on accessible research, Tumori Journal remains an essential resource in the continuous fight against cancer.

Cancers

Transforming cancer knowledge into impactful solutions.
Publisher: MDPIISSN: Frequency: 24 issues/year

Cancers is a leading peer-reviewed journal published by MDPI, dedicated to advancing the field of oncology and cancer research. Established in 2009 and based in Switzerland, this Open Access journal provides a platform for the rapid dissemination of high-quality research findings, reviews, and clinical studies related to all aspects of cancer biology and treatment. With an impressive impact factor and recognized as Q1 in Oncology and Q2 in Cancer Research for 2023, Cancers strives to foster a collaborative environment among researchers, healthcare professionals, and students seeking to deepen their knowledge and understanding of cancer. The journal’s commitment to accessibility and its broad scope make it an invaluable resource for anyone passionate about combating cancer and improving patient outcomes. For more information and to access its diverse publications, visit the journal’s website.

Chinese Clinical Oncology

Exploring cutting-edge methodologies in cancer research.
Publisher: AME PUBLISHING COMPANYISSN: 2304-3865Frequency: 4 issues/year

Chinese Clinical Oncology is a distinguished journal dedicated to advancing the field of oncology and clinical research, published by AME Publishing Company. Since its inception in 2012, this journal has established its significance within the academic community, boasting an impactful presence as evidenced by its 2023 Scopus rankings, where it is positioned in the 47th percentile in the field of oncology. This open access journal features a diverse range of research, reviews, and clinical studies that aim to bridge the gap between experimental and clinical oncology, making it an invaluable resource for researchers, medical professionals, and students alike. The journal is based in Hong Kong and is committed to publishing studies that contribute to the understanding and treatment of cancer, with a strong focus on innovative methodologies and emerging therapies. With a current categorization of Q2 in Medicine and Q3 in Oncology, Chinese Clinical Oncology offers a robust platform for scholarly communication and is pivotal for those involved in cancer research and treatment.

YONAGO ACTA MEDICA

Elevating Peer-Reviewed Medicine to New Heights
Publisher: TOTTORI UNIV MEDICAL PRESSISSN: 0513-5710Frequency: 4 issues/year

YONAGO ACTA MEDICA, published by Tottori University Medical Press, is a prominent journal in the field of Medicine, recognized for its contributions and academic rigor since its inception in 1965. With an ISSN of 0513-5710 and E-ISSN of 1346-8049, this journal is situated in Japan and spans significant periods of convergence from 1965 to 1977 and from 1986 to 2024. Classified within the Q3 category of Medicine (Miscellaneous) and holding a respectable Scopus rank of 275 out of 636 in General Medicine, YONAGO ACTA MEDICA offers an invaluable platform for researchers, professionals, and students to disseminate innovative studies and findings in diverse medical topics. While the journal currently does not operate under an open-access model, it remains committed to promoting academic excellence and advancing medical knowledge through peer-reviewed publications. Address inquiries and contributions to 86 NISHI-CHO, YONAGO, TOTTORI-KEN 683-8503, JAPAN.

PEDIATRIC HEMATOLOGY AND ONCOLOGY

Transforming pediatric care with expert insights and research.
Publisher: TAYLOR & FRANCIS INCISSN: 0888-0018Frequency: 8 issues/year

Pediatric Hematology and Oncology, published by Taylor & Francis Inc, serves as a vital platform dedicated to the fields of hematology, oncology, and pediatrics, providing a comprehensive avenue for the dissemination of scholarly research and clinical advancements. With an ISSN of 0888-0018 and an E-ISSN of 1521-0669, this journal has successfully converged its expertise over the years from 1984 to 2024. Ranked in the Q3 category for Hematology and Oncology, alongside a Q2 ranking in Pediatrics, Perinatology, and Child Health (2023), it engages a diverse readership comprising researchers, healthcare professionals, and students eager to explore groundbreaking studies in child health and treatment methodologies. While it currently does not offer Open Access options, the journal is widely cited and recognized, particularly in its specialized fields, fostering a rich environment for dialogue and innovation in the management of pediatric hematological and oncological disorders. The journal is based in the United Kingdom at 530 Walnut Street, Ste 850, Philadelphia, PA 19106, making it an essential resource for those pursuing excellence in pediatric medical research.

Molecular and Clinical Oncology

Uncovering the molecular secrets of oncology.
Publisher: SPANDIDOS PUBL LTDISSN: 2049-9450Frequency: 12 issues/year

Molecular and Clinical Oncology is a dynamic journal published by SPANDIDOS PUBL LTD, aimed at advancing the understanding of cancer biology and treatment modalities. With an ISSN of 2049-9450 and an E-ISSN of 2049-9469, the journal serves as a critical platform for researchers and clinicians dedicated to uncovering novel insights in molecular oncology and enhancing clinical practices. As a testament to its growing influence, the journal has achieved a Q3 ranking in Oncology and a Q4 ranking in Cancer Research for the year 2023, reflecting its commitment to publishing high-quality research. Although currently not an Open Access publication, the journal offers crucial subscription options, ensuring comprehensive access to groundbreaking studies and innovations in the field. With converged years spanning 2018 to 2024, the journal is set to continue enriching the academic community with its valuable contributions, ultimately empowering researchers, professionals, and students engaged in the fight against cancer.